Notice2021-16377
Agency Forms Undergoing Paperwork Reduction Act Review
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
August 2, 2021
Issuing agencies
Health and Human Services DepartmentCenters for Disease Control and Prevention
Full Text
<html>
<head>
<title>Federal Register, Volume 86 Issue 145 (Monday, August 2, 2021)</title>
</head>
<body><pre>
[Federal Register Volume 86, Number 145 (Monday, August 2, 2021)]
[Notices]
[Pages 41472-41473]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-16377]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-21-21EE]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled Integrated Viral Hepatitis Surveillance and
Prevention Funding for Health Departments (CDC-RFA-PS21-2103) to the
Office of Management and Budget (OMB) for review and approval. CDC
previously published a ``Proposed Data Collection Submitted for Public
Comment and Recommendations'' notice on April 16, 2021 to obtain
comments from the public and affected agencies. CDC received two
comments related to the previous notice. This notice serves to allow an
additional 30 days for public and affected agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
[[Page 41473]]
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570. Comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to <a href="http://www.reginfo.gov/public/do/PRAMain">www.reginfo.gov/public/do/PRAMain</a>. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct
written comments and/or suggestions regarding the items contained in
this notice to the Attention: CDC Desk Officer, Office of Management
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202)
395-5806. Provide written comments within 30 days of notice
publication.
Proposed Project
Integrated Viral Hepatitis Surveillance and Prevention Funding for
Health Departments (CDC-RFA-PS21-2103)--New--National Center for HIV/
AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
In 2021, CDC is implementing activities under a new cooperative
agreement Integrated Viral Hepatitis Surveillance and Prevention
Funding for Health Departments (CDC-RFA-PS21-2103). Tools exist to
prevent new cases of hepatitis A, hepatitis B, and hepatitis C, to
treat people living with hepatitis B, and to cure people living with
hepatitis C. Yet, new cases of viral hepatitis (VH) continue to rise,
many people infected with VH remain undiagnosed, and far too many VH-
related deaths occur in the US each year. The purpose of the activities
under this new cooperative agreement is to enable states to collect
data to evaluate disease burden and trends, and to analyze and
disseminate that data to develop or refine recommendations, policies,
and practices that will ultimately reduce the burden of VH in their
jurisdictions. The goals of the activities are to reduce new VH
infections, VH-related morbidity and mortality, and VH-related
disparities, and to establish comprehensive national VH surveillance,
which are in accordance with the Division of Viral Hepatitis 2025
Strategic Plan.
The activities of the new cooperative agreement are divided into
two components (Component 1: Surveillance, and Component 2:
Prevention), containing six strategies: 1.1, develop, implement, and
maintain a plan to rapidly detect and respond to outbreaks for
hepatitis A, B, and C; 1.2, collect, analyze, interpret, and
disseminate data to characterize trends, and implement public health
interventions for hepatitis A, acute hepatitis B and acute and chronic
hepatitis C; 1.3 (contingent on available funding), collect, analyze,
interpret, and disseminate data to characterize trends and implement
public health interventions for chronic hepatitis B and perinatal
hepatitis C; 2.1, support VH elimination planning and surveillance, and
maximize access to testing, treatment, and prevention; 2.2 (contingent
on available funding), increase access to HCV and HBV testing and
referral to care in high-impact settings; and 2.3 (contingent on
available funding), improve access to services preventing VH among
persons who inject drugs. Contingent on funding, an optional component
(Component 3: Special Projects) will support improved access to
prevention, diagnosis, and treatment of viral, bacterial and fungal
infections related to drug use in settings disproportionately affected
by drug use.
Viral hepatitis case surveillance data will be collected per each
jurisdiction's usual mechanism using variables that have been approved
by OMB separately (OMB Control No. 0920-0728). Performance measures
will be monitored to assess recipient performance, including quality of
data, effective program implementation, and accountability of funds.
Data collection via the Annual Performance Report will be used for
program accountability and to inform performance improvement. Outbreak
reporting will also be submitted throughout the year. These data, which
complement case data as another key component of national viral
hepatitis surveillance, are critical to determining both the level of
viral hepatitis activity within a jurisdiction as well as the
effectiveness of each jurisdiction's approach to cluster and outbreak
response.
CDC requests approval for an estimated 240 annual burden hours.
There is no cost to respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per
Type of respondents Form name respondents responses per response (in
respondent hours)
----------------------------------------------------------------------------------------------------------------
Health Departments.................... APR: Component 1........ 59 1 1
Health Departments.................... APR: Component 2........ 59 1 1
Health Departments.................... APR: Component 3........ 14 1 1
Health Departments.................... Initial Outbreak Report 59 2 20/60
Form.
Health Departments.................... Outbreak Summary Report 59 2 20/60
Form.
Health Departments.................... Acute Viral Hepatitis 59 1 30/60
Case Reporting.
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2021-16377 Filed 7-30-21; 8:45 am]
BILLING CODE 4163-18-P
</pre></body>
</html>Indexed from Federal Register on August 2, 2021.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.